In an interview with Pharm Exec deputy editor Don Tracy, Carlos Doty, vice president and medical head for AstraZeneca’s U.S. oncology business, provides an update on Lynparza’s current research activities and discusses its impact on cancer patients over the past decade.
The impact of Lynparza on cancer treatment
Leave a comment
